Package Leaflet: Information for the User
Olanzapine Flas Qualigen20 mg orodispersible tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Olanzapina Flas Qualigen contains the active substance olanzapine. This medicine belongs to a group of medicines called antipsychotics and is used to treat the following diseases:
This medicine has been shown to prevent the recurrence of these symptoms in patients with bipolar disorder whose manic episodes have responded to treatment with olanzapine.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Olanzapina Flas Qualigen
If you suffer from any of the following diseases, tell your doctor as soon as possible:
If you suffer from dementia, you or your caregiver or family member should inform your doctor if you have ever had a stroke or a lack of blood flow to the brain.
As a routine precaution, if you are over 65 years old, it would be advisable for your doctor to check your blood pressure.
Children and adolescents
Patients under 18 years of age should not take Olanzapina Flas Qualigen.
Other medicines and Olanzapina Flas Qualigen
Only use other medicines at the same time as this medicine if your doctor authorizes it. You may feel a certain sensation of drowsiness if you combine Olanzapina Flas Qualigen with antidepressants or medications for anxiety or that help you sleep (tranquilizers).
Tell your doctor if you are taking, have recently taken, or may need to take any other medicine.
In particular, tell your doctor if you are taking
Use of Olanzapina Flas Qualigen with alcohol
Do not drink alcohol while taking this medicine as the combination with alcohol may cause drowsiness.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or plan to become pregnant, consult your doctor before using this medicine. You should not take this medicine when you are breastfeeding as small amounts of this medicine may pass into breast milk.
The following symptoms may occur in newborn babies of mothers who have been treated with Olanzapina Flas Qualigen in the last trimester of pregnancy (last three months of pregnancy): tremors, stiffness and/or muscle weakness, drowsiness, agitation, breathing problems, and difficulty feeding.
If your baby develops any of these symptoms, you should contact your doctor.
Driving and using machines
There is a risk of drowsiness when taking this medicine. If this happens to you, do not drive vehicles or use machinery. Consult your doctor.
Olanzapina Flas Qualigen contains lactose, aspartame, and sodium.
This medicine contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
This medicine contains 2.12 mg of aspartame in each tablet. Aspartame is a source of phenylalanine that may be harmful in case of phenylketonuria (PKU), a rare genetic disease in which phenylalanine accumulates because the body is unable to eliminate it properly.
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially "sodium-free".
Follow exactly the administration instructions of this medicine indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Your doctor will indicate how many tablets of this medicine you should take and for how long. The daily dose of Olanzapina Flas Qualigen ranges from 5 mg to 20 mg. Consult with your doctor if you suffer from symptoms again but do not stop taking this medicine unless your doctor tells you to.
The tablets of Olanzapina Flas Qualigen should be taken once a day, following the instructions of your doctor. Try to take the tablets at the same time every day. You can take them with or without food. The orodispersible tablets of Olanzapina Flas Qualigen are for oral administration.
The tablets of Olanzapina Flas Qualigen crumble easily, so they should be handled with care. Do not handle the tablets with wet hands because they can disintegrate.
You can also put the tablet in a cup or glass filled with water, orange juice, apple juice, milk, or coffee, stirring. With some drinks, the mixture may change color and take on a cloudy appearance. You should drink it immediately.
If you take more Olanzapina Flas Qualigen than you should
Patients who have taken more Olanzapina Flas Qualigen than they should have experienced the following symptoms: rapid heartbeat, agitation/aggression, speech problems, unusual movements (especially of the face and tongue), and a reduced level of consciousness. Other symptoms may be: acute confusion, seizures (epilepsy), coma, a combination of fever, rapid breathing, sweating, muscle stiffness, and a state of confusion or drowsiness, slowing of respiratory rate, aspiration, increased or decreased blood pressure, and abnormal heart rhythms. Contact your doctor or go to the hospital immediately if you experience any of the above symptoms. Show the doctor the package with the tablets.
You can also consult your pharmacist or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take Olanzapina Flas Qualigen
Take your tablet as soon as you remember. Do not take a double dose to make up for forgotten doses.
If you stop taking Olanzapina Flas Qualigen
Do not stop treatment just because you feel better. It is very important that you continue taking this medicine while your doctor tells you to.
If you stop taking Olanzapina Flas Qualigen suddenly, symptoms such as sweating, insomnia, tremors, anxiety, or nausea and vomiting may appear. Your doctor may suggest that you gradually reduce the dose before stopping treatment.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor immediately if you have:
Very common side effects (which can affect more than 1 in 10 people) include weight gain; drowsiness; and increased prolactin levels in the blood. In the early stages of treatment, some people may feel dizzy or faint (with slower heartbeats), especially when getting up from a lying or sitting position. This feeling usually disappears on its own, but if it does not, consult your doctor.
Common side effects (which can affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating lipids, and temporary increases in liver enzymes at the start of treatment; increased blood sugar and urine levels; increased uric acid and creatine phosphokinase levels in the blood; increased appetite; dizziness; agitation; tremors; unusual movements (dyskinesia); constipation; dry mouth; skin rash; loss of strength; excessive fatigue; fluid retention that causes swelling of the hands, ankles, or feet; fever, joint pain, and sexual dysfunction such as decreased libido in men and women or erectile dysfunction in men.
Uncommon side effects (which can affect up to 1 in 100 people) include hypersensitivity (e.g., inflammation of the mouth and throat, itching, skin rash); diabetes or worsening of diabetes, occasionally related to ketoacidosis (acetone in blood and urine) or coma; seizures, in most cases related to a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; speech problems; stuttering; slow pulse; sensitivity to sunlight; nosebleeds; abdominal distension; excessive salivation; memory loss or forgetfulness; urinary incontinence; loss of urination ability; hair loss; absence or decrease of menstrual periods; changes in the mammary gland in men and women such as abnormal milk production or abnormal growth.
Rare side effects (which can affect up to 1 in 1000 people) include a drop in normal body temperature; abnormal heart rhythm; sudden unexplained death; pancreatitis, which causes severe stomach pain, fever, and discomfort; liver disease, with yellowing of the skin and the white areas of the eyes; muscle disorder that presents as unexplained pain and prolonged and/or painful erections.
Very rare side effects include severe allergic reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS). Initially, DRESS manifests with symptoms similar to the flu with a rash on the face and later with a widespread rash, fever, enlarged lymph nodes, elevated liver enzymes observed in blood tests, and an increase in a type of white blood cell in the blood (eosinophilia).
During treatment with olanzapine, elderly patients with dementia may suffer from stroke, pneumonia, urinary incontinence, falls, extreme fatigue, visual hallucinations, a rise in body temperature, skin redness, and walking problems. Some deaths have been reported in this particular group of patients.
Olanzapina Flas Qualigen may worsen symptoms in patients with Parkinson's disease.
Reporting of side effects
If you experience any side effect, consult your doctor or nurse, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date that appears on the package after
EXP. The expiry date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of via wastewater or household waste. Deposit the packages and medicines you no longer need in the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of packages and medicines you no longer need. This will help protect the environment.
Composition of Olanzapina Flas Qualigen
The active substance is olanzapine. Each orodispersible tablet of Olanzapina Flas Qualigen contains 20 mg of active substance.
The other ingredients are lactose monohydrate, calcium silicate, low-substitution hydroxypropyl cellulose (E-463), crospovidone, aspartame (E-951), orange flavor, banana flavor (contains sodium), anhydrous colloidal silica (E-551), and magnesium stearate (E-470). See section 2 Olanzapina Flas Qualigen contains lactose, aspartame, and sodium.
Appearance of Olanzapina Flas Qualigen 20 mg and contents of the pack
Olanzapina Flas Qualigen 20 mg orodispersible tablets are yellow.
Olanzapina Flas Qualigen 20 mg orodispersible tablets are available in packages of 28 tablets.
Other presentations:
Olanzapina Flas Qualigen 5 mg orodispersible tablets: packages of 28 tablets.
Olanzapina Flas Qualigen 10 mg orodispersible tablets: packages of 28 and 56 tablets.
Olanzapina Flas Qualigen 15 mg orodispersible tablets: packages of 28 tablets.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Neuraxpharm Spain, S.L.U.
Avda. Barcelona, 69
08970 Sant Joan Despí
Barcelona - Spain
Manufacturer:
Neuraxpharm Pharmaceuticals, S.L.
Avda. Barcelona, 69
08970 Sant Joan Despí
Barcelona - Spain
Date of the last revision of this leaflet: 04/2024
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.es/
The average price of OLANZAPINE QUALIGEN 20 mg ORALLY DISINTEGRATING TABLETS in October, 2025 is around 105.78 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.